Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

ERK1/2 anticorps

MAPK1/3 Reactivité: Humain, Souris WB, ELISA, IHC, FACS Hôte: Souris Monoclonal 3F8 unconjugated
N° du produit ABIN1724731
  • Antigène Voir toutes ERK1/2 (MAPK1/3) Anticorps
    ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
    Reactivité
    • 192
    • 160
    • 158
    • 23
    • 22
    • 18
    • 7
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain, Souris
    Hôte
    • 138
    • 55
    • 4
    Souris
    Clonalité
    • 135
    • 62
    Monoclonal
    Conjugué
    • 91
    • 12
    • 8
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    Cet anticorp ERK1/2 est non-conjugé
    Application
    • 150
    • 65
    • 51
    • 48
    • 47
    • 39
    • 22
    • 21
    • 20
    • 13
    • 6
    • 4
    • 4
    • 3
    • 1
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)
    Purification
    purified
    Immunogène
    Purified recombinant fragment of human MAPK expressed in E. coli.
    Clone
    3F8
    Isotype
    IgG2b
    Top Product
    Discover our top product MAPK1/3 Anticorps primaire
  • Indications d'application
    ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000, FCM: 1:200 - 1:400
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Ascitic fluid containing 0.03 % sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C/-20 °C
    Stockage commentaire
    4°C, -20°C for long term storage
  • Lønne, Masoumi, Lennartsson, Larsson: "Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway." dans: The Journal of biological chemistry, Vol. 284, Issue 48, pp. 33456-65, (2009) (PubMed).

  • Antigène
    ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
    Autre désignation
    p44/42 MAPK (Erk1/2) (MAPK1/3 Produits)
    Synonymes
    anticorps erk1/2, anticorps mitogen-activated protein kinase, anticorps erk1/2
    Sujet

    Description: Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines and is an important target in the diagnosis and treatment of cancer. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK and the transcription factor Elk-1. p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs, along with MEK inhibitors such as U0126 and PD98059.

    Aliases: ERK, p38, p40, p41, ERK2, ERT1, MAPK2, PRKM1, PRKM2, P42MAPK, p41mapk, MAPK1

    Poids moléculaire
    42 kDa
    ID gène
    5594
    HGNC
    5594
Vous êtes ici:
Support technique